Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
about
Neuronal nitric oxide inhibits intestinal smooth muscle growthCardioprotective effects of PKG activation by soluble GC activator, BAY 60-2770, in ischemia-reperfusion-injured rat hearts.Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension.Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.Protoporphyrin IX/Cobyrinate Derived Hybrids - Novel Activators of Soluble Guanylyl CyclaseRole of aging versus the loss of estrogens in the reduction in vascular function in female rats.Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells.A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase.Systems biology of HBOC-induced vasoconstriction.New renal drug development to face chronic renal disease.Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension.Synthesis of New Hydrophilic and Hydrophobic Cobinamides as NO-Independent sGC Activators.Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.Desensitization of the soluble guanylyl cyclase/cGMP pathway by lipopolysaccharide in rat isolated pulmonary artery but not aorta.Dynamic change of heme environment in soluble guanylate cyclase and complexation of NO-independent drug agents with H-NOX domain.Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667).Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat.Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy
P2860
Q28570540-99CA1C13-B2F8-4146-86F5-9EA31AC869CAQ33865769-12A0CEC4-D4F7-4FA8-96AA-66D004A55594Q34778575-63FE359D-01D8-4794-863B-B30FB9C1C04EQ35740400-BD3E06C0-17F2-4B43-9039-A8626FCDCF30Q36693586-881137AF-673E-487D-BC50-7E772C2EB2E9Q37072758-44FF6AF3-4A6C-43B7-9007-79E1BBF10533Q37193830-A8AC181C-781E-4567-AE37-232B3708BF43Q37467778-5A5E257E-8A4C-45FC-BFD7-867A45ACBC65Q37897234-F7E5C497-93E3-485C-8403-D5CB9031356AQ38246640-BB2E4336-B155-4409-BB79-AE7D74243BEAQ39382663-501738A2-DDDA-4F9F-BC91-D38856346A8EQ39733766-496181B8-8234-4403-94C3-C893185677CCQ41147581-0568B548-4FA9-4B95-8EC0-1C30A96EA092Q41329824-DE6DFD51-2C73-47B7-99CA-596C9C95B73FQ43223837-4E873624-DFA0-459E-AEBF-EEF9BC57A98DQ43862233-94377C1A-150D-4650-AD70-96C1FA4B7411Q45928615-354631C3-6CCD-42D7-B1F5-3B9202982B1AQ46173433-4A61B228-1FED-4C5A-B668-FC10100A1B35Q53644051-DBB2495B-EFC0-427E-B356-280690C29034Q57098021-C39B2BA7-7B57-40CA-9A79-F5D90F5F0FFE
P2860
Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Nitric oxide-independent stimu ...... 272 in cardiovascular disease.
@en
type
label
Nitric oxide-independent stimu ...... 272 in cardiovascular disease.
@en
prefLabel
Nitric oxide-independent stimu ...... 272 in cardiovascular disease.
@en
P1476
Nitric oxide-independent stimu ...... 272 in cardiovascular disease.
@en
P2093
Guido Boerrigter
John C Burnett
P356
10.1111/J.1527-3466.2007.00003.X
P577
2007-01-01T00:00:00Z